Skip to main content
. 2014 Oct 15;7(10):3181–3192.

Figure 2.

Figure 2

Significantly elevated MDSCs in patients with prostate cancer. A. Mean granulocytic CD33+CD11b+HLA-DR-CD14- MDSCs levels in patients with prostate cancer were significantly higher than age-matched controls and patients with BPH. B. Mean monocytic CD33+CD11b+HLA-DR-CD14+ MDSCs levels in patients with prostate cancer were higher than controls and patients with BPH. C. Mean granulocytic CD33+CD11b+HLA-DR-CD15+ MDSCs levels in patients with prostate cancer were higher than controls and patients with BPH. D. CD33+CD11b+HLA-DR-CD14- MDSCs is the the major phenotype of MDSCs in prostate cancer.